Back to results
US 2026/0240928 A1Published application
Recombinant oncolytic adenovirus for cancer therapy
AssigneesThe Johns Hopkins University, University of Tasmania
InventorsFred Bunz, Andrew Flies
Life of this patent
Estimating the term…
Abstract
Provided herein are recombinant adenoviruses comprising: (a) a modified E1 coding region; (b) an inactive E3 coding region; (c) a HLA-A*02:01 open reading frame; and (d) an immunopeptide sequence present in a capsid protein encoding region, wherein the immunopeptide sequence comprises a p53-derived immunopeptide.
Claims20
A recombinant adenovirus comprising:
- (a) a modified E1 coding region;
- (b) an inactive E3 coding region;
- (c) a HLA-A*02:01 open reading frame;
- and
- (d) an immunopeptide sequence present in a capsid protein encoding region,
- wherein the immunopeptide sequence comprises a p53-derived immunopeptide.
3 more elements
Dependencies are inferred from the claim text.